Gene: DCBLD2
Official Full Name: discoidin, CUB and LCCL domain containing 2provided by HGNC
Gene Summary: Predicted to enable signaling receptor activity. Involved in negative regulation of cell growth and wound healing. Located in cell surface and plasma membrane. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO26566 | DCBLD2 Knockout cell line (HeLa) | Human | DCBLD2 | 1:3~1:6 | Negative | Online Inquiry |
KO26567 | DCBLD2 Knockout cell line (HCT 116) | Human | DCBLD2 | 1:2~1:4 | Negative | Online Inquiry |
KO26568 | DCBLD2 Knockout cell line (HEK293) | Human | DCBLD2 | 1:3~1:6 | Negative | Online Inquiry |
KO26569 | DCBLD2 Knockout cell line (A549) | Human | DCBLD2 | 1:3~1:4 | Negative | Online Inquiry |
DCBLD2 gene knockout cell lines are specialized cellular models engineered to lack the expression of the DCBLD2 gene, a member of the Discoidin domain receptor family involved in various physiological processes, including cellular adhesion, proliferation, and differentiation. The knockout mechanism utilizes CRISPR-Cas9 technology to precisely disrupt the DCBLD2 locus, resulting in the complete ablation of gene function. This allows researchers to study the ramifications of DCBLD2 loss and its impact on cellular behavior and disease pathways.
The key functions of DCBLD2 involve its role in cell signaling, particularly in the context of tumor progression and metastasis. Understanding the biological effects of DCBLD2 knockout on cellular dynamics, such as migration, matrigel invasion, and angiogenesis, can provide insights into its contribution to cancer biology and potential therapeutic targets. These knockout cell lines are invaluable tools for investigating the gene's involvement in various conditions and elucidating the molecular mechanisms underlying DCBLD2-associated pathways.
In research and clinical settings, DCBLD2 gene knockout cell lines present numerous applications, ranging from cancer research to regenerative medicine. By availing models that allow for the detailed analysis of DCBLD2 function, scientists can accelerate drug discovery processes and identify compelling biomarkers for diseases where DCBLD2 is implicated.
Compared to alternative cell lines or gene-editing methods, our DCBLD2 knockout models stand out due to their robustness, reproducibility, and ease of use within existing workflows. Researchers benefit from our comprehensive validation protocols ensuring high specificity and efficiency of the knockout construct.
Ultimately, DCBLD2 gene knockout cell lines represent a significant advancement in the toolkit available to researchers and clinicians alike. They provide a unique opportunity to dissect the biological relevance of DCBLD2 in both health and disease, enabling pivotal discoveries in the field. Our company is dedicated to supporting scientific progress with high-quality, meticulously developed biological products that empower researchers to push the boundaries of knowledge in molecular biology and biotechnology.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.